Stryker Seeks Exemption For Patient-Transport Devices
A petition submitted to the US FDA seeks to exempt class II powered patient-transport devices from premarket notification requirements.
You may also be interested in...
After much wrangling, the US agency finally clarified its position on what evidence can determine “intended use” of a product – and industry is not happy.
Fees for filing a premarket application with the US FDA increased 2.5% for fiscal year 2022, which is significantly less than the 7% they went up last year.
Research from the University of California, San Francisco claims that many deaths involving medical devices are incorrectly reported to the US agency, and says improving the accuracy of how these deaths are classified could improve patient safety.